Skip to main content
SpringerLink
Log in

Ophthalmological Manifestations of Systemic Neoplasia and Its Treatment

  • Reference work entry
  • First Online:
Albert and Jakobiec's Principles and Practice of Ophthalmology

  • 55 Accesses

Abstract

Cancer is a leading cause of death worldwide and affects individuals of all ages, genders, and ethnicities. Although primary ocular cancers are uncommon, patients with systemic malignancy can develop visual problems in three general ways: (1) direct invasion of the eye, orbit, or visual pathways by the primary tumor or metastasis, (2) paraneoplastic phenomena secondary to the development of antibodies in response to the presence of a tumor, and (3) ocular complications related to systemic antineoplastic therapy. Given that patients often seek the services of an ophthalmologist when visual problems develop, ophthalmologists should be aware of these potential ophthalmological manifestations in patients with systemic malignant disease. Further, visual signs and symptoms may precede the diagnosis of an underlying malignancy, making the ophthalmologist an often-critical source of medical care delivery for these patients. This chapter emphasizes the effects of systemic cancer and its treatment on the visual system and does not address primary ocular, orbital, or optic nerve tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 5,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 6,499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Budczies J, von Winterfeld M, Klauschen F, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6(1):570–83.

    Article  PubMed  Google Scholar 

  2. Goldberg RA, Rootman J, Cline RA. Tumors metastatic to the orbit: a changing picture. Surv Ophthalmol. 1990;35(1):1–24.

    Article  CAS  PubMed  Google Scholar 

  3. Maheshwari A, Finger PT. Cancers of the eye. Cancer Metastasis Rev. 2018;37(4):677–90.

    Article  PubMed  Google Scholar 

  4. Georgalas I, Paraskevopoulos T, Koutsandrea C, et al. Ophthalmic metastasis of breast cancer and ocular side effects from breast cancer treatment and management: mini review. Biomed Res Int. 2015;2015:574086.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hoang A, Khine KT, Knight OJ, et al. A rare ocular presentation of metastatic lung cancer: unilateral anterior chamber angle, bilateral choroidal, and multiple intracranial metastases. J Glaucoma. 2017;26(2):e93–5.

    Article  PubMed  Google Scholar 

  6. Celebi AR, Kilavuzoglu AE, Altiparmak UE, et al. Iris metastasis of gastric adenocarcinoma. World J Surg Oncol. 2016;14:71.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Shields CL, Shields JA, Gross NE, et al. Survey of 520 eyes with uveal metastases. Ophthalmology. 1997;104(8):1265–76.

    Article  CAS  PubMed  Google Scholar 

  8. Konstantinidis L, Damato B. Intraocular metastases – a review. Asia Pac J Ophthalmol (Phila). 2017;6(2):208–14.

    Google Scholar 

  9. Sobottka B, Kreissig I. Ultrasonography of metastases and melanomas of the choroid. Curr Opin Ophthalmol. 1999;10(3):164–7.

    Article  CAS  PubMed  Google Scholar 

  10. Cennamo G, Romano MR, Breve MA, et al. Evaluation of choroidal tumors with optical coherence tomography: enhanced depth imaging and OCT-angiography features. Eye (Lond). 2017;31(6):906–15.

    Article  CAS  Google Scholar 

  11. Hernández Pardines F, Molina Martín JC, Fernández Montalvo L, Juárez Marroquí A. Optic nerve metastasis caused by lung adenocarcinoma. Arch Soc Esp Oftalmol. 2017;92(11):552–4.

    Article  PubMed  Google Scholar 

  12. Arnold AC, Hepler RS, Foos RY. Isolated metastasis to the optic nerve. Surv Ophthalmol. 1981;26(2):75–83.

    Article  CAS  PubMed  Google Scholar 

  13. Aghdam KA, Zand A, Sanjari MS. Isolated unilateral infiltrative optic neuropathy in a patient with breast cancer. Turk J Ophthalmol. 2019;49(3):171–4.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cabrera-Beyrouti R, Campos-Mollo E, Rico-Santos E, et al. Eyelid metastasis as first presentation of renal cell carcinoma. Arch Soc Esp Oftalmol. 2017;92(11):547–51.

    Article  CAS  PubMed  Google Scholar 

  15. van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology. 1999;53(2):382–5.

    Article  PubMed  Google Scholar 

  16. Balaji R, Ramachandran K, Kumar A, et al. Pachymeningeal metastasis from squamous cell carcinoma of the uterine cervix with involvement of the optic nerve: case report and review of the literature. Cancer Imaging. 2007;7:138–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Talcott KE, Garg RJ, Garg SJ. Ophthalmic manifestations of leukemia. Curr Opin Ophthalmol. 2016;27(6):545–51.

    Article  PubMed  Google Scholar 

  18. Mashayekhi A, Shukla SY, Shields JA, et al. Choroidal lymphoma: clinical features and association with systemic lymphoma. Ophthalmology. 2014;121:342–51.

    Article  PubMed  Google Scholar 

  19. Bonzheim I, Giese S, Deuter C, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126(1):76–9.

    Article  CAS  PubMed  Google Scholar 

  20. Smith SJ, Diehl NN, Smith BD, Mohney BG. Incidence, ocular manifestations, and survival in children with neuroblastoma: a population-based study. Am J Ophthalmol. 2010;149(4):677–82.e2.

    Article  PubMed  PubMed Central  Google Scholar 

  21. O’Glasser AY, Milas KM. Horner’s, heterochromia, and harlequins. J Gen Intern Med. 2016;31(1):137.

    Article  PubMed  Google Scholar 

  22. Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumour. Nat Rev Nephrol. 2019;15(4):240–51.

    Article  PubMed  Google Scholar 

  23. Kurli M, Finger PT. The kidney, cancer, and the eye: current concepts. Surv Ophthalmol. 2005;50(6):507–18.

    Article  PubMed  Google Scholar 

  24. Alfaar AS, Zamzam M, Abdalla B, et al. Childhood Ewing sarcoma of the orbit. J Pediatr Hematol Oncol. 2015;37(6):433–7.

    Article  PubMed  Google Scholar 

  25. Lawlor ER, Sorensen PH. Twenty years on: what do we really know about Ewing sarcoma and what is the path forward? Crit Rev Oncog. 2015;20(3–4):155–71.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Grativvol RS, Cavalcante WCP, Castro LHM, et al. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Curr Oncol Rep. 2018;20(11):92.

    Article  CAS  PubMed  Google Scholar 

  27. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Canamary AM, Takahashi WY, Sallum JMF. Autoimmune retinopathy: a review. Int J Retina Vitreous. 2018;4:1.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–54.

    Article  PubMed  PubMed Central  Google Scholar 

  30. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist. 2006;11(3):292–305.

    Article  PubMed  Google Scholar 

  31. Sahu JK, Prasad K. The opsoclonus–myoclonus syndrome. Pract Neurol. 2011;11(3):160–6.

    Article  PubMed  Google Scholar 

  32. Ma GM, Chow JS, Taylor GA. Review of paraneoplastic syndromes in children. Pediatr Radiol. 2019;49(4):534–50.

    Article  PubMed  Google Scholar 

  33. Schwenkenbecher P, Chacko L, Pul R, et al. Paraneoplastic cerebellar syndromes associated with antibodies against Purkinje cells. Int J Neurosci. 2018;128(8):721–8.

    Article  CAS  PubMed  Google Scholar 

  34. Moreno TA, Patel SN. Comprehensive review of treatments for bilateral diffuse uveal melanocytic proliferation: a focus on plasmapheresis. Int Ophthalmol Clin. 2017;57(1):177–94.

    Google Scholar 

  35. Klemp K, Kiilgaard JF, Heegaard S, et al. Bilateral diffuse uveal melanocytic proliferation: case report and literature review. Acta Ophthalmol. 2017;95(5):439–45.

    Article  PubMed  Google Scholar 

  36. Niffenegger JH, Soltero A, Niffenegger JS, et al. Prevalence of hepatocyte growth factor and autoantibodies to α-HGF as a new etiology for bilateral diffuse uveal melanocytic proliferation masquerading as neovascular age-related macular degeneration. J Clin Exp Ophthalmol. 2018;9(4):740.

    Google Scholar 

  37. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81(5):606–13.

    Article  CAS  PubMed  Google Scholar 

  38. Volpe NJ, Rizzo JF. Retinal disease in neuro-ophthalmology: paraneoplastic retinopathy and the big blind spot syndrome. Semin Ophthalmol. 1995;10(3):234–41.

    Article  CAS  PubMed  Google Scholar 

  39. Roels D, Ueno S, Talianu CD, et al. Unilateral cancer-associated retinopathy: diagnosis, serology and treatment. Doc Ophthalmol. 2017;135(3):233–40.

    Article  PubMed  Google Scholar 

  40. Hoogewoud F, Butori P, Blanche P, Brézin AP. Cancer-associated retinopathy preceding the diagnosis of cancer. BMC Ophthalmol. 2018;18(1):285.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Grewal DS, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014;34(5):827–45.

    Article  CAS  PubMed  Google Scholar 

  42. Makiyama Y, Kikuchi T, Otani A, et al. Clinical and immunological characterization of paraneoplastic retinopathy. Invest Ophthalmol Vis Sci. 2013;54(8):5424–31.

    Article  CAS  PubMed  Google Scholar 

  43. Cogan DG, Kuwabara T, Currie J, Kattah J. Paraneoplastic retinopathy simulating cone dystrophy with achromatopsia. Klin Monatsbl Augenheilkd. 1990;197(2):156–8.

    Article  CAS  PubMed  Google Scholar 

  44. Abazari A, Allam SS, Adamus G, Ghazi NG. Optical coherence tomography findings in autoimmune retinopathy. Am J Ophthalmol. 2012;153(4):750–6. 6.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Singh AD, Milam AH, Shields CL, et al. Melanoma-associated retinopathy. Am J Ophthalmol. 1995;119(3):369–70.

    Article  CAS  PubMed  Google Scholar 

  46. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001;21(3):173–87.

    Article  CAS  PubMed  Google Scholar 

  47. Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology. 1994;101(7):1236–43.

    Article  CAS  PubMed  Google Scholar 

  48. Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013;58(5):430–58.

    Article  PubMed  Google Scholar 

  49. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54(1):38–50.

    Article  PubMed  Google Scholar 

  50. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175(3):408–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Nanni L, Broccoli A, Nanni C, et al. Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. Leuk Lymphoma. 2018;59(12):2990–3.

    Article  PubMed  Google Scholar 

  52. Wirtz PW, de Keizer RJ, de Visser M, et al. Tonic pupils in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2001;24(3):444–5.

    Article  CAS  PubMed  Google Scholar 

  53. Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2005;159(1–2):230–7.

    Article  CAS  PubMed  Google Scholar 

  54. Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017;264(9):1854–63.

    Article  CAS  PubMed  Google Scholar 

  55. Kinori M, Hodgson N, Zeid JL. Ophthalmic manifestations in neurofibromatosis type 1. Surv Ophthalmol. 2018;63(4):518–33.

    Article  PubMed  Google Scholar 

  56. Bosch MM, Wichmann WW, Boltshauser E, Landau K. Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol. 2006;124(3):379–85.

    Article  PubMed  Google Scholar 

  57. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet. 1995;11(1):90–2.

    Article  CAS  PubMed  Google Scholar 

  58. Neurofibromatosis. Conference statement. National Institutes of Health Consensus development conference. Arch Neurol. 1988;45(5):575–8.

    Google Scholar 

  59. Avery RA, Katowitz JA, Fisher MJ, et al. Orbital/periorbital plexiform neurofibromas in children with neurofibromatosis type 1: multidisciplinary recommendations for care. Ophthalmology. 2017;124(1):123–32.

    Article  PubMed  Google Scholar 

  60. Singh AD, Nouri M, Shields CL, et al. Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease. Ophthalmology. 2001;108(10):1907–11.

    Article  CAS  PubMed  Google Scholar 

  61. Wong WT, Agrón E, Coleman HR, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. Ophthalmology. 2008;115(1):181–8.

    Article  PubMed  Google Scholar 

  62. Hardwig P, Robertson DM. von Hippel-Lindau disease: a familial, often lethal, multi-system phakomatosis. Ophthalmology. 1984;91(3):263–70.

    Article  CAS  PubMed  Google Scholar 

  63. Aronow ME, Wiley HE, Gaudric A, et al. von Hippel-Lindau disease: update on pathogenesis and systemic aspects. Retina. 2019;63(39):2243–53.

    Google Scholar 

  64. Hall HN, Williamson KA, FitzPatrick DR. The genetic architecture of aniridia and Gillespie syndrome. Hum Genet. 2019;138:881–98.

    Google Scholar 

  65. van Heyningen V, Williamson KA. PAX6 in sensory development. Hum Mol Genet. 2002;11(10):1161–7.

    Article  PubMed  Google Scholar 

  66. Schanilec P, Biernacki R. Aniridia: a comparative overview. Am Orthopt J. 2014;64:98–104.

    Article  PubMed  Google Scholar 

  67. Nusliha A, Dalpatadu U, Amarasinghe B, et al. Congenital hypertrophy of retinal pigment epithelium (CHRPE) in patients with familial adenomatous polyposis (FAP); a polyposis registry experience. BMC Res Notes. 2014;7:734.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Dinarvand P, Davaro EP, Doan JV, et al. Familial adenomatous polyposis syndrome: an update and review of extraintestinal manifestations. Arch Pathol Lab Med. 2019;143:1382–98.

    Google Scholar 

  69. Wijn MA, Keller JJ, Giardiello FM, Brand HS. Oral and maxillofacial manifestations of familial adenomatous polyposis. Oral Dis. 2007;13(4):360–5.

    Article  CAS  PubMed  Google Scholar 

  70. Shields JA, Shields CL, Shah PG, et al. Lack of association among typical congenital hypertrophy of the retinal pigment epithelium, adenomatous polyposis, and Gardner syndrome. Ophthalmology. 1992;99(11):1709–13.

    Article  CAS  PubMed  Google Scholar 

  71. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367(6461):375–6.

    Article  CAS  PubMed  Google Scholar 

  72. Castinetti F, Waguespack SG, Machens A, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213–20.

    Article  PubMed  PubMed Central  Google Scholar 

  73. O’Riordain DS, O’Brien T, Crotty TB, et al. Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery. 1995;118(6):936–42.

    Article  PubMed  Google Scholar 

  74. Camacho CP, Hoff AO, Lindsey SC, et al. Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians. Arq Bras Endocrinol Metabol. 2008;52(8):1393–8.

    Article  PubMed  Google Scholar 

  75. Bardenstein DS, McLean IW, Nerney J, Boatwright RS. Cowden’s disease. Ophthalmology. 1988;95(8):1038–41.

    Article  CAS  PubMed  Google Scholar 

  76. Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol. 2015;111(1):125–30.

    Article  PubMed  Google Scholar 

  77. Siordia JA. Medical and surgical management of Carney complex. J Card Surg. 2015;30(7):560–7.

    Article  PubMed  Google Scholar 

  78. Jagan L, Zoroquiain P, Bravo-Filho V, et al. Sebaceous adenomas of the eyelid and Muir-Torre syndrome. Br J Ophthalmol. 2015;99(7):909–13.

    Article  PubMed  Google Scholar 

  79. Wong A, Ngeow J. Hereditary syndromes manifesting as endometrial carcinoma: how can pathological features aid risk assessment? Biomed Res Int. 2015;2015:219012.

    PubMed  PubMed Central  Google Scholar 

  80. Fraunfelder FW, Fraunfelder FT. Interferon alfa-associated anterior ischemic optic neuropathy. Ophthalmology. 2011;118(2):408–11.e1–2.

    Article  CAS  PubMed  Google Scholar 

  81. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89(6–7):884–93.

    Article  CAS  PubMed  Google Scholar 

  82. Bauherz G, Soeur M, Lustman F. Oculomotor nerve paralysis induced by alpha II-interferon. Acta Neurol Belg. 1990;90(2):111–4.

    CAS  PubMed  Google Scholar 

  83. Jacobs AD, Levenson JE, Golde DW. Induction of acute corneal allograft rejection by alpha-2 interferon. Am J Med. 1987;82(1):181–2.

    Article  CAS  PubMed  Google Scholar 

  84. Hager T, Seitz B. Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther. 2013;7:69–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Esmaeli B, Koller C, Papadopoulos N, Romaguera J. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology. 2001;108(5):858–60.

    Article  CAS  PubMed  Google Scholar 

  86. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol. 1996;14(3):1018–26.

    Article  CAS  PubMed  Google Scholar 

  87. Ugurlu S, Karagoz A, Altin Ekin M. Ocular findings in breast cancer patients using tamoxifen. Cutan Ocul Toxicol. 2015;34(1):16–20.

    Article  CAS  PubMed  Google Scholar 

  88. Davis ME. Ocular toxicity of tyrosine kinase inhibitors. Oncol Nurs Forum. 2016;43(2):235–43.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Kheir WJ, Sniegowski MC, El-Sawy T, et al. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Surv Ophthalmol. 2014;59(5):493–502.

    Article  PubMed  Google Scholar 

  90. van Dijk EH, van Herpen CM, Marinkovic M, et al. Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology. 2015;122(9):1907–16.

    Article  PubMed  Google Scholar 

  91. Peponis V, Kyttaris VC, Chalkiadakis SE, et al. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus. 2010;19(6):675–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43(3):267–71.

    Article  CAS  Google Scholar 

  93. Bishop RJ, Ding X, Heller CK, et al. Rapid vision loss associated with fludarabine administration. Retina. 2010;30(8):1272–7.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(3):300–8.

    Article  CAS  PubMed  Google Scholar 

  95. Camuglia JE, Beltz JE, Khurana K, Hall AJ. An unusual cause of visual loss after Herpes zoster ophthalmicus: a case report. Cases J. 2010;3(1):17.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3(12):1683–9.

    Article  CAS  PubMed  Google Scholar 

  97. Stevens SM, McClelland CM, Trusheim JE, Lee MS. Carboplatin-associated cranial neuropathy. Neuroophthalmology. 2018;42(5):302–5.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Gul Baykalir B, Ciftci O, Cetin A, Basak Turkmen N. The protective effect of fish oil against cisplatin induced eye damage in rats. Cutan Ocul Toxicol. 2018;37(2):151–6.

    Article  CAS  PubMed  Google Scholar 

  99. Karakurt Y, Uçak T, Tasli N, et al. The effects of lutein on cisplatin-induced retinal injury: an experimental study. Cutan Ocul Toxicol. 2018;37(4):374–9.

    Article  CAS  PubMed  Google Scholar 

  100. Fındık H, Tumkaya L, Yılmaz A, et al. The protective effects of astaxanthin against cisplatin-induced retinal toxicity. Cutan Ocul Toxicol. 2019;38(1):59–65.

    Article  CAS  PubMed  Google Scholar 

  101. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol. 1982;100(11):1766–72.

    Article  CAS  PubMed  Google Scholar 

  102. Wang MY, Arnold AC, Vinters HV, Glasgow BJ. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol. 2000;130(3):367–8.

    Article  CAS  PubMed  Google Scholar 

  103. Kalra R, Chavada B, Madhani NR, et al. Cyclophosphamide and/or anthracyclines induced epiphora in breast cancer patients: a rare side-effect. Curr Drug Saf. 2018;13(1):62–4.

    Article  CAS  PubMed  Google Scholar 

  104. Palkar AH, Nair AG, Desai RJ, et al. Vincristine-induced neuropathy presenting as ptosis and ophthalmoplegia in a 2-year-old boy. J Pediatr Ophthalmol Strabismus. 2015;52:e34–7.

    Article  PubMed  Google Scholar 

  105. Bay A, Yilmaz C, Yilmaz N, Oner AF. Vincristine induced cranial polyneuropathy. Indian J Pediatr. 2006;73(6):531–3.

    Article  PubMed  Google Scholar 

  106. Kim HJ, Hayek B, Nasser Q, Esmaeli B. Viability of full-thickness skin grafts used for correction of cicatricial ectropion of lower eyelid in previously irradiated field in the periocular region. Head Neck. 2013;35(1):103–8.

    Article  PubMed  Google Scholar 

  107. Rathi VM, Mandathara PS, Vaddavalli PK, et al. Fluid filled scleral contact lens in pediatric patients: challenges and outcome. Cont Lens Anterior Eye. 2012;35(4):189–92.

    Article  PubMed  Google Scholar 

  108. Raja V, Rajagopalan S, Kashab T, Moriarty B. Radiation retinopathy: a mistaken diagnosis of hypertensive retinopathy. Clin Exp Optom. 2007;90(6):468–70.

    Article  PubMed  Google Scholar 

  109. Hamada N, Azizova TV, Little MP. Glaucomagenesis following ionizing radiation exposure. Mutat Res. 2019;779:36–44.

    Article  CAS  Google Scholar 

  110. Roden D, Bosley TM, Fowble B, et al. Delayed radiation injury to the retrobulbar optic nerves and chiasm. Clinical syndrome and treatment with hyperbaric oxygen and corticosteroids. Ophthalmology. 1990;97(3):346–51.

    Article  CAS  PubMed  Google Scholar 

  111. Indaram M, Ali FS, Levin MH. In search of a treatment for radiation-induced optic neuropathy. Curr Treat Options Neurol. 2015;17(1):325.

    Article  PubMed  Google Scholar 

  112. Todokoro D, Kamei S, Goto H, et al. Acute retinal necrosis following herpes simplex encephalitis: a nationwide survey in Japan. Jpn J Ophthalmol. 2019;63(4):304–9.

    Article  PubMed  Google Scholar 

  113. Anderson E, Fantus RJ, Haddadin RI. Diagnosis and management of herpes zoster ophthalmicus. Dis Mon. 2017;63(2):38–44.

    Article  PubMed  Google Scholar 

  114. Port AD, Orlin A, Kiss S, et al. Cytomegalovirus retinitis: a review. J Ocul Pharmacol Ther. 2017;33(4):224–34.

    Article  CAS  PubMed  Google Scholar 

  115. Aleixo AL, Curi AL, Benchimol EI, Amendoeira MR. Toxoplasmic retinochoroiditis: clinical characteristics and visual outcome in a prospective study. PLoS Negl Trop Dis. 2016;10(5):e0004685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Stephens JD, Adam MK, Todorich B, et al. Optical coherence tomography findings in endogenous fungal chorioretinitis, retinitis, and endophthalmitis. Ophthalmic Surg Lasers Imaging Retina. 2017;48(11):894–901.

    Article  PubMed  Google Scholar 

  117. Kashkouli MB, Abdolalizadeh P, Oghazian M, et al. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis. Br J Ophthalmol. 2019;103:1460–5.

    Google Scholar 

  118. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004;101(9):1936–46.

    Article  PubMed  Google Scholar 

  119. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;125(4):435–54.

    Article  PubMed  Google Scholar 

  120. Giannaccare G, Pellegrini M, Bernabei F, et al. Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1341–51.

    Article  PubMed  Google Scholar 

  121. Ogawa Y, Kim SK, Dana R, et al. International chronic ocular graft-vs-host-disease (GVHD) consensus group: proposed diagnostic criteria for chronic GVHD (part I). Sci Rep. 2013;3:3419.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Theophanous C, Irvine JA, Parker P, Chiu GB. Use of prosthetic replacement of the ocular surface ecosystem scleral lenses in patients with ocular chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(12):2180–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Vision Center, Children’s Hospital Los Angeles, Los Angeles, CA, USA

    Ashley Polski & Jesse L. Berry

  2. USC Roski Eye Institute, Keck School of Medicine of USC, University of Southern California (USC), Los Angeles, CA, USA

    Ashley Polski & Jesse L. Berry

  3. Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Dan S. Gombos

  4. The Retinoblastoma Center of Houston, MD Anderson/Texas Children’s Hospital/Baylor College of Medicine/Houston Methodist, Research Institute, Houston, TX, USA

    Dan S. Gombos

Authors
  1. Ashley Polski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesse L. Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan S. Gombos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley Polski .

Editor information

Editors and Affiliations

  1. Casey Eye Institute, Oregon Health & Science, Portland, OR, USA

    Daniel M. Albert

  2. Department of Ophthalmology, Massachusetts Eye and Ear, Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Joan W. Miller

  3. Department of Ophthalmology, University of Illinois College of Medicine, University of Illinois at Chicago, Chicago, IL, USA

    Dimitri T. Azar

  4. Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA

    Lucy H. Young

Section Editor information

  1. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylania, Philadelphia, USA

    Joan Marie O’Brien

  2. Department of Ophthalmology, Retina Service, Harvard Medical School; Massachusetts Eye and Ear Infirmary, Boston, MA, USA

    Evangelos S. Gragoudas

  3. The MD Anderson Cancer Center, Texas, USA

    Dan S. Gombos

  4. Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, USA

    Mary E. Aronow

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Polski, A., Berry, J.L., Gombos, D.S. (2022). Ophthalmological Manifestations of Systemic Neoplasia and Its Treatment. In: Albert, D.M., Miller, J.W., Azar, D.T., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-030-42634-7_263

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42634-7_263

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-42633-0

  • Online ISBN: 978-3-030-42634-7

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation